S&P 500   3,390.68 (-0.30%)
DOW   27,463.19 (-0.80%)
QQQ   282.33 (+0.66%)
AAPL   116.44 (+1.21%)
MSFT   212.95 (+1.37%)
FB   283.21 (+2.20%)
GOOGL   1,599.47 (+0.96%)
AMZN   3,290.00 (+2.59%)
TSLA   423.76 (+0.83%)
NVDA   535.27 (+1.83%)
BABA   317.14 (+3.35%)
CGC   18.66 (+0.70%)
GE   7.10 (-3.79%)
MU   51.96 (-0.35%)
AMD   79.55 (-3.26%)
T   26.92 (-1.68%)
F   7.92 (-1.37%)
ACB   4.00 (-9.09%)
GILD   60.00 (+0.07%)
NFLX   488.10 (-0.03%)
NIO   28.44 (+9.34%)
BA   155.24 (-3.48%)
DIS   123.31 (-0.60%)
S&P 500   3,390.68 (-0.30%)
DOW   27,463.19 (-0.80%)
QQQ   282.33 (+0.66%)
AAPL   116.44 (+1.21%)
MSFT   212.95 (+1.37%)
FB   283.21 (+2.20%)
GOOGL   1,599.47 (+0.96%)
AMZN   3,290.00 (+2.59%)
TSLA   423.76 (+0.83%)
NVDA   535.27 (+1.83%)
BABA   317.14 (+3.35%)
CGC   18.66 (+0.70%)
GE   7.10 (-3.79%)
MU   51.96 (-0.35%)
AMD   79.55 (-3.26%)
T   26.92 (-1.68%)
F   7.92 (-1.37%)
ACB   4.00 (-9.09%)
GILD   60.00 (+0.07%)
NFLX   488.10 (-0.03%)
NIO   28.44 (+9.34%)
BA   155.24 (-3.48%)
DIS   123.31 (-0.60%)
S&P 500   3,390.68 (-0.30%)
DOW   27,463.19 (-0.80%)
QQQ   282.33 (+0.66%)
AAPL   116.44 (+1.21%)
MSFT   212.95 (+1.37%)
FB   283.21 (+2.20%)
GOOGL   1,599.47 (+0.96%)
AMZN   3,290.00 (+2.59%)
TSLA   423.76 (+0.83%)
NVDA   535.27 (+1.83%)
BABA   317.14 (+3.35%)
CGC   18.66 (+0.70%)
GE   7.10 (-3.79%)
MU   51.96 (-0.35%)
AMD   79.55 (-3.26%)
T   26.92 (-1.68%)
F   7.92 (-1.37%)
ACB   4.00 (-9.09%)
GILD   60.00 (+0.07%)
NFLX   488.10 (-0.03%)
NIO   28.44 (+9.34%)
BA   155.24 (-3.48%)
DIS   123.31 (-0.60%)
S&P 500   3,390.68 (-0.30%)
DOW   27,463.19 (-0.80%)
QQQ   282.33 (+0.66%)
AAPL   116.44 (+1.21%)
MSFT   212.95 (+1.37%)
FB   283.21 (+2.20%)
GOOGL   1,599.47 (+0.96%)
AMZN   3,290.00 (+2.59%)
TSLA   423.76 (+0.83%)
NVDA   535.27 (+1.83%)
BABA   317.14 (+3.35%)
CGC   18.66 (+0.70%)
GE   7.10 (-3.79%)
MU   51.96 (-0.35%)
AMD   79.55 (-3.26%)
T   26.92 (-1.68%)
F   7.92 (-1.37%)
ACB   4.00 (-9.09%)
GILD   60.00 (+0.07%)
NFLX   488.10 (-0.03%)
NIO   28.44 (+9.34%)
BA   155.24 (-3.48%)
DIS   123.31 (-0.60%)
Log in
NASDAQ:HOTH

Hoth Therapeutics Stock Forecast, Price & News

$1.76
-0.04 (-1.94 %)
(As of 10/27/2020 02:03 PM ET)
Add
Compare
Today's Range
$1.77
Now: $1.77
$1.96
50-Day Range
$1.79
MA: $2.03
$2.41
52-Week Range
$1.73
Now: $1.77
$7.25
Volume400 shs
Average Volume453,613 shs
Market Capitalization$23.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. It intends to use the BioLexa Platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has license agreements with the George Washington University; the University of Maryland Baltimore; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Zylö Therapeutics, Inc.; Chelexa BioSciences, Inc.; and the University of Cincinnati. Hoth Therapeutics, Inc. was founded in 2017 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HOTH
CUSIPN/A
CIKN/A
Phone646-756-2997
Employees2

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.24 per share

Profitability

Net Income$-7,700,000.00

Miscellaneous

Market Cap$23.71 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$1.76
-0.04 (-1.94 %)
(As of 10/27/2020 02:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HOTH News and Ratings via Email

Sign-up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions

How has Hoth Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Hoth Therapeutics' stock was trading at $3.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HOTH shares have decreased by 54.0% and is now trading at $1.7650.
View which stocks have been most impacted by COVID-19
.

When is Hoth Therapeutics' next earnings date?

Hoth Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Hoth Therapeutics
.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.06.
View Hoth Therapeutics' earnings history
.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a drop in short interest during the month of September. As of September 30th, there was short interest totaling 27,700 shares, a drop of 40.7% from the September 15th total of 46,700 shares. Based on an average daily volume of 700,100 shares, the short-interest ratio is currently 0.0 days. Currently, 0.3% of the shares of the company are sold short.
View Hoth Therapeutics' Short Interest
.

Who are some of Hoth Therapeutics' key competitors?

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu BioScience (AYTU), Gilead Sciences (GILD), Ibio (IBIO) and Nabriva Therapeutics (NBRV).

Who are Hoth Therapeutics' key executives?

Hoth Therapeutics' management team includes the following people:
  • Mr. Robb Knie, Pres, CEO & Chairman (Age 51, Pay $525k)
  • Ms. Jane H. Behrmann, VP of Operations (Age 35, Pay $123.78k)
  • Mr. David S. Briones, Chief Financial Officer (Age 44)
  • Dr. Stefanie Johns Ph.D., Chief Scientific Officer

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 1,300,000 shares at $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

How do I buy shares of Hoth Therapeutics?

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $1.77.

How big of a company is Hoth Therapeutics?

Hoth Therapeutics has a market capitalization of $23.71 million. Hoth Therapeutics employs 2 workers across the globe.

What is Hoth Therapeutics' official website?

The official website for Hoth Therapeutics is www.hoththerapeutics.com.

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]

This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.